Ortholoc 2 Lapifuse
Payments companies reported to CMS as associated with Ortholoc 2 Lapifuse. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ortholoc 2 Lapifuse, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ortholoc 2 Lapifuse
These are the largest totals companies reported as associated with Ortholoc 2 Lapifuse. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jeremy Mccormick | Saint Louis, MO | Foot and Ankle Surgery | $234,015.42 |
| William Davis | Charlotte, NC | Orthopaedic Surgery | $208,094.38 |
| Jesse Doty | Chattanooga, TN | Orthopaedic Surgery | $204,487.42 |
| Ryan Scott | Phoenix, AZ | Foot & Ankle Surgery | $113,671.25 |
| Christopher Hyer | Worthington, OH | Foot & Ankle Surgery | $85,874.71 |
| Krupa Patel | Morris Plains, NJ | Foot & Ankle Surgery | $83,036.96 |
| John Clements | Roanoke, VA | Podiatrist | $75,121.78 |
| Eric Tan | Los Angeles, CA | Foot and Ankle Surgery | $66,574.83 |
| Stephen Brigido | Bethlehem, PA | Foot & Ankle Surgery | $60,851.56 |
| Matthew Sorensen | Algonquin, IL | Foot & Ankle Surgery | $53,883.88 |
Prescribed Ortholoc 2 Lapifuse?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.